Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
€ 0.13
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly undervalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Carmat SA designs and develops total artificial heart for people suffering from end-stage biventricular heart failure in France and internationally. It The company was founded in 2008 and is headquartered in Vélizy-Villacoublay, France.
Company Valuation
From both historical and forecast perspectives, the stock is considerably underpriced compared to similar stocks.
Data is available to registered users only
